Zacks Investment Research downgraded shares of Sunesis Pharmaceuticals (NASDAQ:SNSS) from a strong-buy rating to a hold rating in a report published on Thursday.
According to Zacks, “Sunesis Pharmaceuticals is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel small molecule therapeutics for oncology and other serious diseases. It has built a broad product candidate portfolio through internal discovery and in-licensing of novel cancer therapeutics. It is advancing its product candidates through in-house research and development efforts and strategic collaborations with leading pharmaceutical and biopharmaceutical companies. “
Other analysts have also issued research reports about the company. ValuEngine raised Sunesis Pharmaceuticals from a sell rating to a hold rating in a research note on Wednesday, January 2nd. HC Wainwright started coverage on Sunesis Pharmaceuticals in a research note on Thursday, December 20th. They issued a neutral rating and a $0.50 price target for the company. Four analysts have rated the stock with a hold rating and one has given a buy rating to the stock. Sunesis Pharmaceuticals has an average rating of Hold and an average target price of $1.75.
Sunesis Pharmaceuticals (NASDAQ:SNSS) last announced its quarterly earnings results on Monday, November 5th. The biopharmaceutical company reported ($0.18) EPS for the quarter, topping analysts’ consensus estimates of ($0.22) by $0.04. As a group, analysts expect that Sunesis Pharmaceuticals will post -0.81 EPS for the current fiscal year.
About Sunesis Pharmaceuticals
Sunesis Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of oncology therapeutics for the treatment of solid and hematologic cancers. Its lead program is vecabrutinib, a non-covalently binding inhibitor of Bruton's tyrosine kinase (BTK), which is in Phase 1b/2 clinical trial in B-cell malignancies.
See Also: What is the Quick Ratio?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Sunesis Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sunesis Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.